16156-56-2

Usage

InChI:InChI=1/C7H14O3S/c1-11(8,9)10-7-5-3-2-4-6-7/h7H,2-6H2,1H3

Upstream product

• 1001-62-3 bis(methanesulfonyl)peroxide 
• 110-82-7 cyclohexane 
• 75-75-2 methanesulfonic acid 
• 108-93-0 cyclohexanol 
• 709-83-1 2-(cyclohexyloxy)tetrahydro-2H-pyran 
• 124-63-0 methanesulfonyl chloride 
• 7143-01-3 Methanesulfonic anhydride 
• 13871-89-1 trimethylsilyl cyclohexyl ether 

Downstream Products

• 3289-28-9 ethyl cyclohexanecarboxylate 
• 110-83-8 cyclohexene 
• 25109-28-8 4-bromo(cyclohexyl)benzene 
• 59734-92-8 1-bromo-2-cyclohexylbenzene 
• 3042-69-1 1-cyclohexylnaphthalene 
• 42044-07-5 2-cyclohexylnaphthalene 
• 4501-52-4 2-cyclohexyl-p-xylene 
• 2206-48-6 2-cyclohexylanisole 
• 613-36-5 4-cyclohexylanisole 
• 4516-10-3 1-cyclohexyl-2,4,6-trimethylbenzene 
• 827-52-1 1-phenyl-1-cyclohexane 
• 20005-52-1 2,5-dicyclohexyl-4-methylphenol 
• 7226-88-2 2,6-dicyclohexyl-4-methylphenol 
• 1596-09-4 2-Cyclohexyl-4-methyl-phenol 

Relevant academic research and scientific papers

An Assessment of the Causes of the "Cesium Effect"

Cesium alkanoates (chiefly the propionate) have been investigated for their solubility, nucleophilic, reactivity and degree of ion pairing in dimethylformamide (DMF) and, in some cases, dimethyl sulfoxide (DMSO) solutions. 133Cs NMR has been used to establish the degree of ion pairing.From the data obtained it is concluded that the cesium ion is virtually completely solvated and that the carboxylates are essentially free and highly reactive.The consequences of this effect on macrocyclization by means of nucleophilic substitution are discussed.

Identification of organophosphorus simulants for the development of next-generation detection technologies

Organophosphorus (OP) chemical warfare agents (CWAs) represent an ongoing threat but the understandable widespread prohibition of their use places limitations on the development of technologies to counter the effects of any OP CWA release. Herein, we describe new, accessible methods for the identification of appropriate molecular simulants to mimic the hydrogen bond accepting capacity of the PO moiety, common to every member of this class of CWAs. Using the predictive methodologies developed herein, we have identified OP CWA hydrogen bond acceptor simulants for soman and sarin. It is hoped that the effective use of these physical property specific simulants will aid future countermeasure developments.

Electrochemical Deoxygenative Thiolation of Preactivated Alcohols and Ketones

This work describes an electrochemically promoted nickel-catalyzed deoxygenative thiolation of alcohols and ketones under mild conditions. Excellent substrate tolerance and good chemical yields can be achieved by graphene/nickel foam electrodes in an undivided cell. Further study to gain mechanistic insight into this electrochemical cross-coupling has been carried out.

TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS

Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.

Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis

Calcium dependent protein kinase 1 (CDPK1) is an essential Ser/Thr kinase that controls invasion and egress by the protozoan parasite Toxoplasma gondii. The Gly gatekeeper of CDPK1 makes it exquisitely sensitive to inhibition by small molecule 1H-pyrazolo

CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS

The present invention provides cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications as described herein.

Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity

Wogonin, a natural product isolated from the plant Scutellaria baicalensis, has been shown to be a potent and selective inhibitor of CDK9. With the purpose of investigating the activity and selectivity of this chemical scaffold, several series of wogonin derivatives were prepared and screened for CDK9 inhibition and cellular antiproliferative activity. Among these compounds, the drug-like compound 51 showed potent activity against CDK9 (IC50 = 19.9 nM) and MV4-11 cell growth (IC50 = 20 nM). In addition, compound 51 showed much improved physicochemical properties, such as water solubility, compared with the parent compound wogonin. The follow-up studies showed that the compound 51 is selective toward CDK9-overexpressing cancer cells over normal cells. Preliminary mechanism studies on the anticancer effect indicated that 51 inhibited the proliferation of MV4-11 cells via caspase-dependent apoptosis. In addition, highlighted compound 51 showed significant antitumor activity in mouse acute myeloid leukemia (AML) models without producing apparent toxic effects in vivo, which gave us a new tool for further investigation of CDK9-targeted inhibitor as a potential antitumor drug especially for AML.

AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS

Provided herein are aminopyridine derivatives and pharmaceutical compositions that are useful as TAM family kinase inhibitors.

Iron(III)-catalyzed halogenations by substitution of sulfonate esters

A novel halogenation reaction from sulfonates catalyzed by iron(III) is described. The reaction can be performed as a stoichiometric or a catalytic version. This reaction provides a convenient strategy for the efficient access to structurally diverse secondary chlorides, bromides and iodides. The stereochemical course of the reaction is governed by the substrate and the experimental conditions. Secondary alcohols modified as quisylates or pysylates are substantially more reactive. Aliphatic quisylates proceed with overall inversion of configuration under catalytic conditions. Chemoselectivity in bismesylates was observed in favour of the secondary mesylate. Additionally, based on the experimental results, a possible catalytic cycle for the halogenation has been proposed.

PYRAZOLE COMPOUNDS AS JAK INHIBITORS

The present invention relates to compounds of formula (I), wherein R1, R2, R1a, R1b have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.